SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
MTNB

Matinas BioPharma Holdings, Inc. (New York Stock Exchange Arca:MTNB)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.80-$0.01 (-1.26%)
 
Market cap
$342K
Insider Score
Health Score
Analyst consensus
Listed since
Jul 21, 2014
Market Cap$341.62K-93.3%
Revenue (ttm)$0
Net Income-$6.92M+60.4%
EPS-$21.45+59.0%
Shares Out427.08K
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume37,089
Open$0.77
Previous Close$0.81
Day's Range$0.75 - $0.80
52-Week Range$0.75 - $14.63
Beta1.70
AnalystsBuy
Price Targetn/a
Earnings DateApr 1, 2027
-1.25% (1D)
No price history available.

About MTNB

Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.

Address
1545 Route 206 South, Bedminster, NJ, 07921, US
Market Cap
0 million
Employees
2
Industrial Classification
Biotechnology
Financial Health Score
Fair
From MTNB’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-1.26%
5 Days
-14.44%
1 Month
-53.22%
6 Months
-92.43%
1 Year
-93.25%

$MTNB stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in MTNB holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by MTNB's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

MTNB Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New MTNB patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to MTNB from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in MTNB

VXFVanguard Extended Market ETF$4.04K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from MTNB’s recent data — informational, not investment advice

Generating analysis…

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.